Please login to the form below

Not currently logged in
Email:
Password:

cost

This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

NHS England says it will save £300m by negotiating deals with five manufacturers on low cost versions of adalimumab, which has been the single biggest drug cost for the health service

Latest news

More from news
Approximately 9 fully matching, plus 2,596 partially matching documents found.

Latest Intelligence

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    NICE basic cost-effectiveness threshold to be retained at the current range (£20, 000 £30, 000 per quality-adjusted life year) for the duration of the voluntary scheme. ... the government dictates, or forcing all companies into a statutory scheme, is

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Regulators, payers and large, organised customers expect to see an evidence package that includes impact on cost of illness, burden of illness, quality of life and impact on caretakers. ... Despite these relatively new levers of cost control, early

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.

  • Diagnosed Anywhere Diagnosed Anywhere

    Around the globe, the cost and waiting game to see a doctor will drive growth and utilisation of alternate diagnostic tools, at a moment when innovators large and small are uncovering

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    CAR-T therapies are cost-effective for these patients, but the service redesign required is just as big a challenge.”. ... James Roach. Many of England’s acute providers are ‘technically bankrupt’, he says, requiring an accelerated move to more

More from intelligence
Approximately 2 fully matching, plus 410 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 337 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics